drugset / Trial / NCT02706626
Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors
Phase 2
Terminated
32 enrolled
Criterium, Inc.
Academic Thoracic Oncology Medical Investigators Consortium · collabDuke University · collabGeorgetown University · collabOhio State University · collabTakeda · collabUniversity of Colorado, Denver · collabUniversity of Pittsburgh · collabUniversity of Texas Southwestern Medical Center · collabVanderbilt University · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of this investigational drug, brigatinib (AP261136) in patients with advanced non-small cell lung cancer Non-small cell lung cancer (NSCLC) who have had first-line treatment for their cancer and it still got worse, even after, or while taking drugs called ALK inhibitors, or anti-cancer drugs that act on tumors. Some examples of these anti-cancer drugs are: KEYTRUDA® or ALECENSA®).
Timeline
- Start
- 2017-03-09
- Primary completion
- 2020-10-08
- Completion
- 2021-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brigatinib | Small molecule | 180 mg | — |
| Subject | Brigatinib | Small molecule | 240 mg | — |